¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Glial Cell Line-Derived Neurotrophic Factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • endothelial cell
    ³»ÇǼ¼Æ÷
  • enterochromaffine cell
    âÀÚÅ©·Òģȭ¼¼Æ÷, ÀåÅ©·Òģȭ¼¼Æ÷
  • enteropathy-type T-cell lymphoma
    À庴ÁõÇüT¼¼Æ÷¸²ÇÁÁ¾
  • eosinophilic cell
    È£»ê¼¼Æ÷
  • ependymal cell
    ³ú½Ç¸·¼¼Æ÷
  • epidermal cell
    Ç¥ÇǼ¼Æ÷
  • epithelial cell
    »óÇǼ¼Æ÷
  • epithelioid cell
    »óÇǸð¾ç¼¼Æ÷
  • epithelioid cell nevus
    »óÇǸð¾ç¼¼Æ÷¸ð¹Ý
  • erythroid cell
    ÀûÇ÷±¸
  • established cell line
    È®¸³¼¼Æ÷ÁÖ
  • ethmoidal air cell
    ¹úÁý, »ç°ñºÀ¼Ò
  • ethmoidal cell
    ¹úÁý, »ç°ñºÀ¼Ò
  • eukaryotic cell
    ÁøÇÙ¼¼Æ÷
  • fat cell
    Áö¹æ¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • erythroid cell
    (¢¡red blood cell) ÀûÇ÷±¸
  • ethmoidal cell
    ¹úÁý»À¹úÁý, »ç°ñºÀ¼Ò
  • ethmoidal air cell
    ¹úÁý»À¹úÁý, »ç°ñ¹úÁý
  • eukaryotic cell
    ÁøÇÙ¼¼Æ÷
  • fat cell
    Áö¹æ¼¼Æ÷
  • fat-storing cell
    Áö¹æÀúÀå¼¼Æ÷
  • flagellated cell
    Æí¸ð¼¼Æ÷
  • foam cell
    °Åǰ¼¼Æ÷
  • follicle cell
    ¼ÒÆ÷¼¼Æ÷, ³­Æ÷¼¼Æ÷
  • follicular cell
    (¢¡follicle cell) ¼ÒÆ÷¼¼Æ÷, ³­Æ÷¼¼Æ÷
  • foreign body giant cell
    À̹°°Å´ë¼¼Æ÷
  • fusiform cell
    (¢¡spindle cell) ¹æÃß¼¼Æ÷
  • ganglion cell
    ½Å°æÀý¼¼Æ÷
  • germ cell
    Á¾ÀÚ¼¼Æ÷, ¹è¾Æ¼¼Æ÷, »ý½Ä¼¼Æ÷
  • germinal cell
    Á¾ÀÚ¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • ganglion cell layer
    ½Å°æÀý¼¼Æ÷Ãþ(¡­öµ).
  • ganglion cell layer
    ½Å°æÀý¼¼Æ÷Ãþ
  • ganglion cell, spiral
    ³ª¼±½Å°æÀý¼¼Æ÷
  • gastrointestinal endocrine cell
    À§Ã¢ÀÚ³»ºÐºñ¼¼Æ÷
  • genetics, somatic cell
    ü¼¼Æ÷À¯ÀüÇÐ
  • germ cell
    »ý½Ä¼¼Æ÷(ßæãÖá¬øà), ¹è¼¼Æ÷(ÛÏá¬øà).
  • germ cell
    Á¾ÀÚ¼¼Æ÷
  • germ cell
    ¹è¾Æ¼¼Æ÷
  • germ cell aplasia
    »ý½Ä¼¼Æ÷Çü¼º °á¿©
  • germ cell determinant
    ¹è¼¼Æ÷°áÁ¤ÀÎÀÚ(ÛÏá¬øà̽ïÒì×í­).
  • germ cell tumor
    »ý½Ä¼¼Æ÷Á¾(ßæãÖá¬øàðþ)
  • germ cell tumors
    »ý½Ä¼¼Æ÷ Á¾¾ç
  • germinal cell
    ¹è¾Æ¼¼Æ÷
  • ghost cell
    ¼¼Æ÷ÂßÀïÀÌ, ¼¼Æ÷²®Áú
  • ghost cell
    À¯·É¼¼Æ÷(ËôËçËṴ̂).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • lipotropic factor
    Ä£Áö¹æ¼º ÀÎÀÚ, Áö¿ë¼º ÀÎÀÚ(¡­ì×í­).
  • lung correction factor
    Æóº¸Á¤°è¼ö
  • lupus erythematosus factor =LE f.
    È«¹Ý¼º ·çǪ½ºÀÎÀÚ(ûõÚèàõ¡­ì×í­).
  • luteinizing hormone releasing factor =LHRF
    Ȳüȭȣ¸£¸óÀ¯¸®<¹æÃâ>ÀÎ ÀÚ(üÜô÷ûù¡­<Û¯õó>ì×í­).
  • luteotrop(h)ic hormone inhibitory factor =LTHIF
    ȲüÀÚ±ØÈ£¸£¸ó¾ïÁ¦ÀÎÀÚ(üÜô÷ô§Ð½¡­åäð¤ì×í­).
  • lymphocyte activating factor
    ¸²ÇÁ±¸È°¼ºÀÎÀÚ
  • lymphocyte activating factor (LAF)
    ¸²ÇÁ±¸ Ȱ¼ºÈ­ÀÎÀÚ
  • lymphocyte inhibitory factor (LIF)
    ¸²ÇÁ±¸¾ïÁ¦ÀÎÀÚ
  • lymphocyte-derived chemotactic factor
    ¸²ÇÁ±¸À¯·¡ È­ÇÐÁÖ¼ºÀÎÀÚ
  • lymphocytosis promoting factor
    ¸²ÇÁ±¸Áõ°¡Áõ ÃËÁøÀÎÀÚ
  • lymphocytosis promoting factor
    ¸²ÇÁ±¸Áõ°¡Áõ ÃËÁø ÀÎÀÚ
  • lymphocytosis stimulating factor =LSF
    ¸²ÇÁ±¸Áõ°¡ÀÚ±ØÀÎÀÚ(¡­Ï¹ñòÊ¥ô§Ð½ ì×í­).
  • lymphocytosis-promoting factor
    ¸²ÇÁ±¸Áõ´ÙÁõÃËÁøÀÎÀÚ
  • lytic factor
    ¿ëÇØÀÎÀÚ(éÁú°ì×í­).
  • macrophage activating factor (MAF)
    ´ë½Ä¼¼Æ÷ Ȱ¼ºÀÎÀÚ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • sulfation factor
    Ȳ»êÈ­ ÀÎÀÚ (üÜß«ûùì×í­)
  • surface factor
    Ç¥¸éÀÎÀÚ (øúØüì×í­)
  • termination factor
    Á¾·áÀÎÀÚ (ðûÖõì×í­)
  • T factor
    T ÀÎÀÚ (ì×í­)
  • third factor
    Á¦»ïÀÎÀÚ (ð¯ß²ì×í­)
  • three-factor cross
    »ïÀÎÀÚ ±³Â÷ (ß²ì×í­Îßó©)
  • thymic humoral factor
    Èä¼± ü¾×ÀÎÀÚ (ýØàÊô÷äûì×í­)
  • thymidine factor
    ŸÀ̵̹ò ÀÎÀÚ (ì×í­)
  • thyrotropic hormone releasing factor
    °©»ó¼±ÀÚ±Ø(Ë£ßÒàÍí©Ð½) È£¸£¸ó À¯¸®ÀÎÀÚ(ë´×îì×í­)
  • time factor effect
    ½Ã°£ÀÎÀÚ È¿°ú (ãÁÊàì×í­üùÍý)
  • tissue factor
    Á¶Á÷ÀÎÀÚ (ðÚòÄì×í­)
  • transfer factor
    "ÀüÀÌ(ï®ì¹) ÀÎÀÚ(ì×í­), Àü´ÞÀÎÀÚ(îîÓ¹ì×í­)"
  • transforming growth factor
    º¯Çü ¼ºÀå ÀÎÀÚ(ܨû¡à÷íþ ì×í­)
  • translocation factor
    ÀüÀ§ ÀÎÀÚ(ï®êÈì×í­)
  • TR factor
    TR ÀÎÀÚ(ì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
LRSF lactating rat serum factor; liver regenerating serum factor
LTF lactotransferrin; lipotropic factor; lymphocyte-transforming factor
MAF macrophage activation factor; macrophage agglutinating factor; maximum atrial fragmentation; minimum...
OAF open air factor; osteoclast activating factor
OGF ovarian growth factor; oxygen gain factor
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
AECA Anti-endothelial cell antibodies
RBC Anti-red blood cell
SRBC Anti-sheep red blood cell
ADCC Antibody Dependent Cell Cytotoxicity
ADCC Antibody Dependent Cell-Mediated Cytotoxicity
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Deiters cell
    ´ÙÀÌÅ׸£½º ¼¼Æ÷
    ³»ÀÌÀÇ ´ÞÆØÀ̰ü ³»ÀÇ ±âÀú¸· À§¿¡ ÀÖ´Â ÄÚ¸£Æ¼±â¸¦ ±¸¼ºÇÏ´Â ÀÏÁ¾ÀÇ ¼¼Æ÷. Á÷Á¢ ¼Ò¸® °¨°¢À» ¹Þ´Â ¿ÜÀ¯¸ð¼¼Æ÷ °£±ØÀ» ä¿ì°í ÀÖ´Â ÁöÁö¼¼Æ÷.
  • delta cell tumor
    µ¨Å¸ ¼¼Æ÷ Á¾¾ç
    ¼Ò¸¶Å佺ŸƾÀ» ºÐºñÇÏ´Â Á¾¾çÀ¸·Î ¼Ò¸¶Å佺ŸƾÁ¾
  • diploid cell
    2¹èü ¼¼Æ÷
    Á¤»óÀÇ 2¹è¼ºÀÇ ¿°»öü, ¶Ç´Â 2°³ÀÇ ÇÙÀ» °¡Áø ¼¼Æ÷. Á¤»óÀÎ Á¶Á÷ ¾È¿¡¼­´Â ¼öÁ¤¶õÀ̳ª ¼¶À¯¾Æ¼¼Æ÷¿¡¼­ º¼ ¼ö ÀÖ´Ù. ÀΰøÀûÀ¸·Î´Â HVJ³ª NDA µîÀÇ ¹ÙÀÌ·¯½º³ª
  • direct cell division
    Á÷Á¢ ¼¼Æ÷ ºÐ¿­
  • disintegrated cell
    ºØ±« ¼¼Æ÷
  • dorsal horn cell
    Èİ¢ ¼¼Æ÷, ¹è°¢ ¼¼Æ÷
  • dorsal horn pain transmission cell
    ¹è°¢ ÅëÁõ Àü´Þ ¼¼Æ÷, ¹è°¢ µ¿Åë Àü´Þ ¼¼Æ÷
  • ductal cell
    µµ°ü ¼¼Æ÷
  • ductule cell
    ¼Ò°ü ¼¼Æ÷
  • ealry squamous cell calcinoma
    ÃÊ±â ÆíÆò»óÇÇ ¼¼Æ÷¾Ï
    ±¸°­ ³» °¡Àå ÈçÇÑ ¾Ç¼º ÁúȯÀ̰í Ä¡°úÀǻ簡 Ä¡·áÇÏ´Â ¸î ¾È µÇ´Â Ä¡¸íÀû ÁúȯÀÇ ÇϳªÀÌ´Ù. Çǰ³ »óÇÇ ¼¼Æ÷ÀÇ ¾Ç¼º ¾ÏÁ¾¼º Áõ½ÄÀÌ´Ù. ¹é¹ÝÁõÀ̶ó°í ÇÏ´Â ÀÓ»ó ¿ë¾î·Îµµ ºÒ¸®´Â ¼Ò»ó »óÇÇ ºñÈÄ¿Í µ¿ÀÏÇÑ º´¼Ò¸¦ º¸¿©ÁØ´Ù. °¡Àå ÈçÇÑ ¿øÀÎÀ¸·Î »ý°¢µÇ´Â °ÍÀº ½À°üÀûÀÎ Èí¿¬°ú ¾ËÄÝÀÌ´Ù. ±¸°­ Á¡¸·¿¡ ¼Ò»ó ¹é»ö ¹ÝÁ¡À» ¸¸µå´Âµ¥ ÀÌ´Â »ý¸®Àû °ú°¢È­¿Í ºñ½ÁÇÏ°Ô º¸ÀδÙ. º´¼Ò¸¦ °ÇÁ¶½ÃŲ ÈÄ ÀÚ¼¼È÷ °üÂûÇϸé ÀÌÇü¼º º´¼ÒÀÇ Ç¥¸éÀÌ ÀϹÝÀûÀ¸·Î ´õ °ÅÄ¥°í ÂÞ±ÛÂÞ±ÛÇÑ °ÍÀ» º¼ ¼ö ÀÖ´Ù.
  • educated T cell
    Ç׿øÀ¸·Î °¨ÀÛµÈ T ¼¼Æ÷
    In vivo ¶Ç´Â in vitro¿¡¼­ Ç׿ø ÀÚ±ØÀ» ¹Þ¾Æ ¸é¿ª ±âÀüÀ» ¹ßÇöÇÒ ¼ö ÀÖ´Â »óŰ¡ µÈ T ¼¼Æ÷ÀÌ´Ù. In vivo¿¡¼­´Â ÀϹÝÀûÀ¸·Î Ä¡»ç·®ÀÇ ¹æ»ç¼±À» Á¶»çÇÑ Áã¿¡ ´Ù¸¥ µ¿¹°·ÎºÎÅÍÀÇ Èä¼± ¼¼Æ÷¸¦ ÀÌÀÔÇÔ°ú µ¿½Ã¿¡ Ç׿øÀÚ±ØÀ» ÇÏ´Â ¹æ¹ýÀÌ »ç¿ëµÈ´Ù.
  • endosteal cell
    °ñ³» ¼¼Æ÷
    À§Ä¡¿¡ ÀÇÇØ º¯°æµÇ°í, È®ÀεǴ ¸Á»ó ¼¼Æ÷. °ñ ³»¸·Àº °ñ¼ö ±âÁúÀÌ ³óÃàµÈ »óÅ´Ù.
  • endothelial cell
    ³»ÇÇ ¼¼Æ÷
  • enkephalinergic cell
    ¿£ÄÉÆÈ¸°¼º ¼¼Æ÷
  • eosinophilic cell
    È£»ê±¸
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
factor <pharmacology> Any of several substances or activities that are necessary to produce a result, for example a coagulation factor.
Often, use of the term factor indicates that the chemical nature of the substance or its mechanism of action is unknown, as in endocrinology, where factors are renamed as hormones when their chemical nature is determined.
(18 Nov 1997)
factor 3 Operational name given to an incompletely characterised selenium-containing natural product which, in minute amounts, prevents liver damage in rats due to deficiency of vitamin E, factor III in the vitamin B12 series, 5-hydroxybenzimidazole, analogue of the usual B12 nucleotide components.
(05 Mar 2000)
factor A A component of the properdin system; a hydrazine-sensitive b1-globulin (mw about 180,000), now known to be C3 (third component of complement).
(05 Mar 2000)
factor analysis, statistical A set of statistical methods for analyzing the correlations among several variables in order to estimate the number of fundamental dimensions that underlie the observed data and to describe and measure those dimensions. It is used frequently in the development of scoring systems for rating scales and questionnaires.
(12 Dec 1998)
factor B <enzyme> A glycine-rich, heat-labile beta-glycoprotein found in blood. It is a proactivator of complement 3 in the alternate pathway of complement activation. Factor b is converted by factor d to c3 convertase.
Registry number: EC 3.4.21.47
(12 Dec 1998)
factor D <enzyme> A serum protein which during the alternate pathway of complement activation converts the inactive properdin factor b to c3 convertase.
Registry number: EC 3.4.21.46
(12 Dec 1998)
factor E A serum protein (mw 160,000) required for activation of C3 (third component of complement) by cobra venom factor.
See: properdin system.
(05 Mar 2000)
factor Gm A factor that determines certain of the allotypes of human immunoglobulins; found only on the g chains of IgG (gamma-globulin).
(05 Mar 2000)
factor H Former designation for biotin, vitamin B12 analogue or precursor, a glycoprotein that regulates the activity of complement factor C3b; a deficiency results in the lack of inhibition of the alternative haemolytic pathway leading to continuous activation and consumption of factor C3 (haemolytic uraemic syndrome).
(05 Mar 2000)
factor I <haematology> A protein which is synthesised by the liver.
Fibrinogen is converted to fibrin, in the formation of a blood clot, via the enzymatic action of thrombin. A fibrinogen assay measures the concentration of fibrinogen in the blood and may be used to evaluate abnormal blood clotting.
A lack of fibrinogen may be congenital or acquired. A condition known as DIC results in the excessive utilisation and depletion of fibrinogen.
Synonym: fibrinogen.
(15 Nov 1997)
factor II <haematology> A protein which is synthesised by the liver.
Fibrinogen is converted to fibrin, in the formation of a blood clot, via the enzymatic action of thrombin. A fibrinogen assay measures the concentration of fibrinogen in the blood and may be used to evaluate abnormal blood clotting.
A lack of fibrinogen may be congenital or acquired. A condition known as DIC results in the excessive utilisation and depletion of fibrinogen.
Synonym: thrombin.
(15 Nov 1997)
factor IIa <enzyme> Protease (34 kD) generated in blood clotting that acts on fibrinogen to produce fibrin. Consists of two chains, A and B, linked by a disulphide bond. B chain has sequence homology with pancreatic serine proteases: cleaves at Arg Gly.
Thrombin is produced from prothrombin by the action either of the extrinsic system (tissue factor + phospholipid) or, more importantly, the intrinsic system (contact of blood with a foreign surface or connective tissue). Both extrinsic and intrinsic systems activate plasma factor X to form factor Xa which then, in conjunction with phospholipid (tissue derived or platelet factor 3) and factor V, catalyses the conversion.
(18 Nov 1997)
factor II assay A test used to measure the activity of a blood clotting factor (thrombin). This test may be used to evaluate excessive bleeding. Abnormally low factor II assays may be seen in the following conditions: congenital deficiency of factor II, fat malabsorption, heparin administration, cirrhosis, vitamin K deficiency and warfarin administration.
(27 Sep 1997)
factor II deficiency A congenital or acquired disorder of blood clotting where there is a deficiency of factor II (prothrombin), one of 20 necessary plasma proteins for normal blood coagulation. Acquired factor II deficiency may result from vitamin K deficiency, severe liver disease and anticoagulant drugs.
Symptoms include abnormal bleeding, nosebleeds, abnormal menstrual bleeding, easy bruising and umbilical cord bleeding at birth. Treatment involves the infusion of fresh frozen plasma. Vitamin K may be administered in select cases.
(27 Sep 1997)
factor III In the clotting of blood, tissue factor or thromboplastin; it initiates the extrinsic pathway by reacting with factor VII and calcium to form factor VIIa.
See: thromboplastin.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
ÅëÇÕ°Ë»ö ¿Ï·á